Weekly Digest - November 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - November 2024
07 Nov 2024: ADC Therapeutics axes lead solid tumor drug after phase 1 setback, pivots to preclinical programs
- ADC Therapeutics has stopped the development of its lead solid tumor candidate, ADCT-601, due to an unfavorable benefit-risk profile identified in a phase 1b trial
- ADCT-601 is an AXL-directed antibody-drug conjugate (ADC) combining an anti-AXL antibody with a PBD-dimer toxin, aiming to target AXL, a receptor associated with poor survival in various tumors
- Initial signs of antitumor activity were observed during the dose-escalation phase, but these were not sustained, leading to inadequate results in the dose-optimization and expansion phases of the trial
- ADC Therapeutics is focusing on the development of new exatecan-based ADCs in preclinical stages, targeting Claudin-6 and NaPi2b, with plans to advance these candidates towards IND-enabling stages
